Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

ABSTRACT:

Purpose

Treatment decisions for patients with T1a,bN0M0 breast cancer are challenging. We studied the time trends in use of adjuvant chemotherapy and survival outcomes among these patients.

Patients and methods

This was a prospective cohort study within the National Comprehensive Cancer Network Database that included 4,113 women with T1a,bN0M0 breast cancer treated between 2000 and 2009. Tumors were grouped by size (T1a, T1b), biologic subtype defined by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, and receipt of chemotherapy with or without trastuzumab.

Results

Median follow-up time was 5.5 years. Eight percent of patients with HR-positive/HER2-negative tumors were treated with chemotherapy. Fifty-two percent of those with HER2-po

SUBMITTER: Vaz-Luis I 

PROVIDER: S-EPMC4076026 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature